Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermagraft, Profore · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold |
| Reference Therapy | ACTIVE_COMPARATOR | Profore - Four-layer compression bandaging therapy |
| Name | Type | Description |
|---|---|---|
| Dermagraft | DEVICE | Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum). |
| Profore | DEVICE | Four-layer compression bandaging therapy. |
Inclusion Criteria: 1. Subject has completed study ABH-Dermagraft-001-08 2. Subject understands study requirements 3. Subject is available to participate in the 1 year-long observational follow-up. Exclusion Criteria: 1. Subject who withdrew or was terminated from ABH-Dermagraft-001-08 before com...
Dermagraft is used for the treatment of venous leg ulcers. It is an investigational product that has been studied in a Phase 3 clinical trial. The trial was a long-term follow-up to the DEVO pivotal trial, which evaluated Dermagraft in patients with venous leg ulcers.
Dermagraft is being developed by Takeda Pharmaceutical Company Limited, which is listed on the stock exchange under the ticker TAK. The company conducted a Phase 3 clinical trial to evaluate the product for the treatment of venous leg ulcers.
Dermagraft is in Phase 3 clinical development. It has been studied in a Phase 3 trial that has been completed. The trial was a long-term follow-up to the DEVO pivotal trial, which evaluated Dermagraft for the treatment of venous leg ulcers.
Dermagraft has been studied in one clinical trial with the identifier NCT01891760. This Phase 3 trial was a long-term follow-up to the DEVO pivotal trial of Dermagraft for treating venous leg ulcers. The trial enrolled 225 participants and has been completed.
Dermagraft is also known as Profore. Both names refer to the same product, which is being developed by Takeda Pharmaceutical Company Limited for the treatment of venous leg ulcers. The product has been evaluated in a Phase 3 clinical trial.